Drug
Turoctocog Alfa Pegol
Turoctocog Alfa Pegol: highest development phase Phase 3, developed by Novo Nordisk. 1 trial record tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Novo Nordisk
Trials
| Drug | Phase | Indication |
|---|---|---|
| turoctocog alfa pegol NCT01731600 | Phase 3 | Congenital Bleeding Disorder |
Latest
No recent events.
Follow Turoctocog Alfa Pegol on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.